JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome
A phase 2 clinical trial indicates that the medication tofacitinib can safely reduce chronic immune overactivity in individuals with Down syndrome, leading to improvements in inflammatory skin conditions.
🔬ResearchPhoto: Medical Xpress
Key points
- Tofacitinib effectively reduced systemic inflammation and interferon activity in trial participants.
- Patients showed marked improvement in chronic inflammatory skin conditions like hidradenitis suppurativa.
- Preliminary neuropsychological data showed positive trends, but further controlled research is required to confirm cognitive benefits.
Researchers at the University of Colorado Anschutz's Linda Crnic Institute have conducted a phase 2 clinical trial investigating the use of tofacitinib, a JAK inhibitor, in adolescents and adults with Down syndrome. The study, published in Cell Reports Medicine, suggests that targeting the excessive interferon signaling caused by an extra copy of chromosome 21 can effectively lower systemic inflammation without compromising normal immune defenses.
Participants in the trial, who also suffered from inflammatory skin conditions such as hidradenitis suppurativa and alopecia areata, received the medication twice daily for 16 weeks. Results showed significant reductions in inflammatory markers and metabolites, including neurotoxic quinolinic acid. Furthermore, patients experienced clinical improvements in their skin conditions and reported better quality of life scores.
While the study also noted improvements in certain neuropsychological tests related to memory and attention, researchers caution that these findings are preliminary. Because the trial lacked a placebo control group, it is unclear if these cognitive changes were a direct result of the medication or other external factors. The study met its primary safety endpoints, though larger, long-term trials are necessary to fully establish the safety and efficacy of this treatment approach.
What to know: This study is an early-stage clinical trial. Patients should consult with their healthcare providers regarding any treatment decisions, as JAK inhibitors carry known risks that require careful medical monitoring.
Source Medical Xpress — medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clini… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…